Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Centre Oscar Lambret
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
City of Hope Medical Center
University Health Network, Toronto
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
Valo Therapeutics Oy
Herlev Hospital
Thomas Jefferson University
City of Hope Medical Center
Centre Hospitalier Universitaire Vaudois
University of Pennsylvania
National Institutes of Health Clinical Center (CC)
BioEclipse Therapeutics
M.D. Anderson Cancer Center
Fate Therapeutics
Fate Therapeutics
University of Pennsylvania
Fate Therapeutics
BGI, China
BGI, China
Karolinska University Hospital
Genocea Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Mie University
Turnstone Biologics, Corp.
Jonsson Comprehensive Cancer Center
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Louisiana State University Health Sciences Center Shreveport
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Mie University
Mayo Clinic
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Massachusetts General Hospital
Shenzhen Second People's Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Northwestern University
City of Hope Medical Center